Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.

Published

Journal Article

OBJECTIVE: The BARI 2D trial compared insulin provision (IP) versus insulin sensitization (IS) for the primary outcome of total mortality in participants with T2DM and cardiovascular disease (CVD). In this analysis we examine baseline characteristics that are associated with successful long-term glycemic control. RESEARCH DESIGN AND METHODS: In a 2×2 factorial design, 2368 participants were randomized to either IP or IS therapy, and to either prompt revascularization with medical therapy or medical therapy alone. Successful long-term glycemic control (success) was defined by simultaneously meeting 1) a mean HbA1c level of <7.0% after each participant's third year of follow-up period, and 2) adherence with medications only from the assigned glycemic treatment arm during >80% of the BARI 2D follow-up. The association between baseline variables and success was determined using unadjusted and adjusted logistic regression models. RESULTS: 1917 participants (962 IP and 955 IS participants) had sufficiently long follow-up and data for this analysis. Among these IP and IS participants, 235 and 335 participants met both criteria of success, respectively (p<0.001). Those not on insulin at entry had higher odds of success (OR 2.25; CI 1.79-2.82) when treated with IS versus IP medications, irrespective of baseline HbA1c levels. Younger age, shorter duration of T2DM, and lower HbA1c at baseline were also each independently associated with higher success when treated with IS versus IP medications. CONCLUSION: Patients similar to those in the BARI 2D trial may have a higher chance of achieving success with IS versus IP medications if they are younger, have shorter duration of T2DM, have lower HbA1c levels, have moderate or strenuous physically activity, and are not on insulin. In contrast, increasing age, longer duration of T2DM, higher HbA1c, and insulin therapy are associated with increased chance of success if treated with IP medications.

Full Text

Duke Authors

Cited Authors

  • Ismail-Beigi, F; Lombardero, MS; Escobedo, J; Genuth, S; Green, J; Massaro, E; Mooradian, AD; Ovalle, F; Whitehouse, F; Zonszein, J; BARI 2D Study Group,

Published Date

  • January 2014

Published In

Volume / Issue

  • 28 / 1

Start / End Page

  • 101 - 109

PubMed ID

  • 23478173

Pubmed Central ID

  • 23478173

Electronic International Standard Serial Number (EISSN)

  • 1873-460X

Digital Object Identifier (DOI)

  • 10.1016/j.jdiacomp.2013.01.006

Language

  • eng

Conference Location

  • United States